Adia Med Inc

AI-generated fair value estimate for this company.

Method: Revenue-multiple (DCF not meaningful pre-scale): ~$1.4M forward annualized revenue (2x Q2 FY26 run-rate of $485K, vs FY25 total of $700K); 8x revenue multiple (high-growth regenerative-medicine/biologics niche, first profitable quarter just reported); no debt; 94.4M shares outstanding.

Reasoning: Adia Med (formerly Adia Nutrition, OTCQB, files 10-Ks) is pivoting into stem-cell/biologics with triple-digit YoY revenue growth off a tiny base and just turned its first profitable quarter, so a forward-revenue multiple is more defensible than a DCF given no FCF history.